Federal action on specialty drug costs sought by Medicaid directors

The National Association of Medicaid Directors is urging House and Senate leaders to take "immediate federal action" to address specialty drugs' high prices. The directors in the letter said lawmakers have failed to address the cost and reimbursement issues associated with high-cost specialty drugs. “Federal thinking on Medicaid financing must reflect” the reality of specialty drug costs, the directors said. “Simply put, the federal Medicaid statute is not designed to allow states to respond to this new pricing approach for pharmaceuticals.”

You can read the full article via Bloomberg BNA here.